{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
nalidixic acid
to a specific field?
Status:
Investigational
Source:
NCT03678610: Not Applicable Interventional Completed Infertility
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Ionomycin is an ionophore produced by the bacterium Streptomyces conglobatus. The molecules act as a motile Ca2+ carrier and enhances Ca2+ influx by direct stimulation of store-regulated cation entry across biological membranes. It is highly specific for divalent cations. Ion selectivity is as follows: Ca2+ > Mg2+ >> Sr2+ = Ba2+ Binding of Sr2+ and Ba2+ is insignificant and binding to monovalent cations or rubidium is negligible. La2+ is also bound to some extent. Complexation with a cation is always in a 1:1 stoichiometry and pH-dependent. Essentially no binding of Ca2+ occurs below pH 7.0 and maximum binding takes place at pH 9.5. At the micromolar level, ionomycin can activate Ca2+/Calmodulin dependent kinase and phosphatase to stimulate gene expression. Ionomycin has been shown to induce central demyelination, inhibit adrenal bovine TREK-1 channels, and to regulate cell division of mature human B cells [1]. It is used to study the effects of calcium flux on endoplasmic reticulum (ER) stress, mitochodrial stress and intrinsic apoptosis mechanisms. It is also used to stimulate the intracellular production of the cytokines, interferon, perforin, IL-2, and IL-4 usually in conjunction with PMA.
Status:
Investigational
Source:
NCT03801889: Phase 2 Interventional Withdrawn Iron Overload
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
SP-420 is iron chelator developed by University Of Florida Research Foundation for the treatment of iron overload disease
Status:
Investigational
Source:
NCT04467905: Phase 2 Interventional Completed Atrial Fibrillation
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Etripamil is a non-dihydropyridine, L-type calcium channel blocker. Currently, etripamil is in Phase 3 development for the treatment of paroxysmal supraventricular tachycardia. Milestone Pharmaceuticals is also developing etripamil to provide rapid heartbeat control for patients living with atrial fibrillation and acute symptom relief for patients with angina.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Nicametate is a vasodilator, which enhances blood flow and oxygen to the brain, aids stroke recovery. It also can use for treating intermittent claudication in certain patients.
Class (Stereo):
CHEMICAL (UNKNOWN)
FENIROFIBRATE, (-)- is a metabolite of fenofibrate, an antilipemic agent which reduces both cholesterol and triglycerides in the blood.
Status:
Investigational
Source:
NCT00063219: Phase 2 Interventional Completed Carcinoma, Non-Small-Cell Lung
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Milataxel, a taxane that binds to and stabilizes tubulin, resulting in the inhibition of microtubule depolymerization. Milataxel has completed phase II clinical trials for non-small cell lung cancer patients, and for colorectal cancer patients. Besides, it was studied for malignant mesothelioma. However, the drug has been discontinued due to toxicity issues at the dose level of 35 mg/m 2.
Status:
Investigational
Source:
USAN:DIATRIZOATE SODIUM I 125 [USAN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
USAN:DIATRIZOATE SODIUM I 131 [USAN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT04052516: Phase 2 Interventional Completed Non Alcoholic Steatohepatitis (NASH)
(2019)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Icosabutate (also known as PRC-4016 or NST-4016), a cholesterol ester transfer protein inhibitor was developed by NorthSea Therapeutics for the treatment of combined dyslipidemias and hypertriglyceridemia. Icosabutate successfully completed phase II clinical trial for hypertriglyceridemic subjects, where was studied the drug efficacy and safety. In April 2018 NorthSea Therapeutics announced that its lead product, icosabutate would be further developed as an effective and safe therapeutic approach to treating both non-alcoholic steatohepatitis and its associated comorbidities.
Status:
Investigational
Source:
NCT02342691: Phase 1/Phase 2 Interventional Completed Gingival Inflammation
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Benzo-lipoxin A4 as a bLXA4-ME also known as ClinRinse-1 participated in phase II clinical trials for the treatment of gingival diseases. It was shown that nano-proresolving medicines (NPRM) containing a lipoxin analog (benzo-lipoxin A4, bLXA4) was a mimetic of endogenous resolving mechanisms with potent bioactions. That offered a new therapeutic tissue-engineering approach for the treatment of chronic osteolytic inflammatory diseases.
